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Splicing into Senescence: Minireview
The Curious Case
of p16 and p19ARF
These genetic lesions often appear to be mutually exclu-
sive within any given tumor, suggesting that they consti-
tute equivalent steps in a single critical pathway (see
Sherr, 1996).
While initially controversial, the role of p16 in familial
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melanoma is now firmly established. Analyses of mela-
noma pedigrees, defined by the presence of multipleThe study of tumor suppressor genes generates much
affected individuals over multiple generations within aof its excitement from the convergence of experiments
family, have demonstrated germline p16 mutations inaddressing the genetic basis of cancer, together with
approximately 50% of families (Hussussian et al., 1994).the cellular pathways that regulate cellular proliferation,
Such pedigrees are rare, but 5%±10% of all melanomaimmortality, and cell cycle progression. Among the most
patients have at least one other affected family member;notable of these gene products is the cyclin-dependent
z20% of individuals with this more common and moder-kinase inhibitor p16 (also known as CDKN2, MTS-1, and
ate family history have a germline mutation in p16 (Fitz-INK4a), implicated in cell cycle regulation and cellular
Gerald et al., 1996). Germline mutations in p16 are typi-senescence, whose loss results in genetic predisposi-
cally point mutations or small intragenic deletions withintion to malignant melanoma and pancreatic cancer (for
the first exon (1a) or second exon. Rare cases of familialreview, see Hall and Peters, 1996). In this issue of Cell,
melanoma have also been linked to a specific pointKamijo and coworkers (1997) report that much of the
mutation in CDK4 (called R24C) (Zuo et al., 1996), whichphenotype ascribed to p16-null mice may in fact be
renders the encoded protein insensitive to inhibition byattributed to disruption of p19ARF, an alternatively spliced
p16, supporting the relevance of this functional pathwaytranscript derived from genomic sequence shared with
in conferring genetic predisposition to melanoma.the p16 transcript but encoding a different open reading
Somatic Disruption of the p16 Locus in Primaryframe. These unexpected observations challenge previ-
Tumors and in Immortalized Cell Linesous assumptions about the unique role of p16 in cancer
The identification of p16 as a tumor suppressor genepredisposition and cellular immortalization, suggesting
implicated in familial melanoma was associated with thedistinct and potentially complementary functions for the
discovery of genomic deletions at that locus in a largetwo transcripts encoded by this complex locus.
number of cell lines derived from many tumor typesGenetic Predisposition to Melanoma and p16
(leading to the name multiple tumor suppressor 1 orThe discovery of p16 and its role in tumor predisposition
resulted from advances in two disparate fields, cancer
genetics and cell cycle regulation. The search for the
familial melanoma gene led to the identification of ge-
netic linkage to chromosome 9p, which was soon fol-
lowed by the discovery of homozygous deletions at that
locus in melanoma cell lines. Within the minimal deleted
region lay p16 (Kamb et al., 1994), previously identified
by virtue of the interaction of its encoded protein with
the cyclin-dependent kinase 4 (CDK4) (Serrano et al.,
1993). Like other members of the cyclin-dependent ki-
nase inhibitor (CKI) family, p16 is a negative regulator of
cyclin-CDK complexes (reviewed in Sherr and Roberts,
1995). p16 itself binds preferentially to CDK4 (hence the
name inhibitor of kinase 4 or INK4) and CDK6, preventing
their association with D-type cyclins and the ensuing
phosphorylation of substrates such as the retinoblas-
toma protein pRB (see Figure 1). Expression of p16 thus
maintains pRB in a hypophosphorylated and active
form, leading to repression of E2F-DP complexes and
G1 phase cell cycle arrest (reviewed in Weinberg, 1995).
The identification of p16 as a tumor suppressor gene Figure 1. Schematic Representation of p16 and Postulated p19ARF
was confirmed by the demonstration of intragenic muta- Pathways
tions, both in the germline and in somatic tissues. The The p16 pathway is simplified in this diagram. However, alterations
in p16, CDK4, Cyclin D, and pRB appear to be mutually exclusiveimportance of this cell cycle regulatory pathway in the
within an individual tumor, suggesting that they have functionallydevelopment of cancer has been underscored by alter-
equivalent consequences. The inability of p19ARF to induce cell cycleations in other components of this pathway. For exam-
arrest in cells lacking p53 suggests a functional pathway, althoughple, in addition to disruption of p16, human cancers may
the inactivation of p53 in some tumors derived from p19ARF-null mice
demonstrate mutational inactivation of RB, overexpres- indicates that inactivation of these two genes is not functionally
sion of D-type cyclins and CDKs, or a CDK4 mutation equivalent (Kamijo et al., 1997). The locus containing p16 and p19ARF
has also been called the INK4a-ARF locus.that abrogates inhibition of the gene product by p16.
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Figure 2. Genomic Structure of the p16-p19ARF Locus
The origin of the p15, p16, and p19ARF transcripts is represented schematically, along with a representative depiction of genomic deletions,
point mutations (arrows), and promoter methylation (arrowheads) noted in human cancers. The exons targeted by Serrano et al. (1996) and
Kamijo et al. (1997) are shown in green, with the direction of the neo casette indicated by an arrow. Blue boxes denote open reading frame
1 (ORF 1) constituting the p16 transcript, red boxes indicate ORF 2 comprising the p19ARF mRNA, and yellow boxes represent p15 exons.
Curved arrows denote the presumptive promoters for the three transcripts. For simplicity, the locus is not drawn to scale; genomic analysis
of the human locus containing p16 and p19ARF indicates that it is approximately 30 kb and that exons 1b and 1a are separated by z20 kb
(Mao et al., 1995; Stone et al., 1995).
MTS-1). In primary tumors, somatic inactivation of p16 amounts of p16 as they approach the limit of their life-
span in vitro (Hara et al., 1996) and that forced expres-is noted primarily in pancreatic cancer, esophageal can-
sion of activated Ha-ras in primary cells induces senes-cer, glioblastoma, and acute T-cell lymphoblastic leuke-
cence that is relieved following inactivation of either p16mia, and may occur by a number of different mecha-
or p53 (Serrano et al., 1997). The apparent link betweennisms. In pancreatic cancer, p16 is disrupted in the
loss of p16 and cellular immortality and tumorigenesismajority of cases, either by small intragenic mutations
was recently addressed by the targeted disruption ofor by large genomic deletions that span the p16 locus.
exon 2 of p16 in mice (Serrano et al., 1996). p16-nullTumors without p16 mutations frequently show hyper-
mice developed fibrosarcomas and lymphomas (70%methylation of a CpG island that extends from the pro-
developed tumors at a mean age of 29 weeks), whichmoter into exon 1a, associated with silencing of tran-
were enhanced by topical application of the carcinogenscription (Merlo et al., 1995) (see Figure 2).
DMBA combined with ultraviolet irradiation (60% of ho-The frequent occurrence of gross genomic deletions
mozygous null mice developed tumors with a compara-spanning the p16 locus in primary tumors and in tumor-
ble histology by 9 weeks and 17% of heterozygous micederived cell lines raised the possibility that additional
developed less aggressive tumors at 15 weeks). Mousegenes might be disrupted. It is possible that these dele-
embryo fibroblasts (MEFs) grew for multiple passagestions simply reflect the presence of sequence-specific
in culture without passing through a characteristic crisiselements that favor such genomic rearrangements, but
and were readily transformed by Ha-ras alone, a prop-they may also be selected as an effective mechanism
erty of cells that have already sustained an immortalizingfor inactivating two contiguous genes in a single genetic
event (Serrano et al., 1996). This view of p16 and itsevent. Adjacent to p16 lies the gene encoding one of
direct role in cellular immortalization and tumorigenesisits homologs, p15 (also known as INK4b), which demon-
is now challenged by the experiments of Kamijo andstrates comparable binding and inhibition of CDK4 and
coworkers, who suggest that the knockout phenotype
CDK6 activity. p15 is frequently deleted along with p16
may be explained in large part by disruption not of p16,
in tumors, but it has not been found to be a specific
but of p19ARF, an alternatively spliced transcript whose
target for deletions or definitive point mutations. None- product is completely distinct from p16 in its sequence
theless, the p15 promoter has been found to be silenced and functional properties.
by hypermethylation in cases of leukemia and gliomas p19ARF: A Dark Horse Emerging
that do not also demonstrate hypermethylation of the from a Splicing Variation
p16 promoter, raising the possibility of an independent Studies of the INK4a locus in both human and mouse
contribution in some human cancers. cells revealed a novel transcript with 39 sequence identi-
The striking frequency of p16 inactivation in tumor- cal to p16 but with a unique 59 end (Duro et al., 1995;
derived cell lines suggests that inactivation of this pro- Mao et al., 1995; Quelle et al., 1995; Stone et al., 1995).
tein plays an important role in the cellular immortaliza- This transcript, called p19ARF (for alternative reading
tion events that accompany the establishment of growth frame) is derived from a distinct first exon (exon 1b) that
in culture. Consistent with this model are the observa- is 13±20 kb centromeric to the first exon of p16 (exon
1a). Exon 1b is spliced to exon 2, which is shared withtions that cultured primary cells express increasing
Minireview
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p16, but this occurs in a different reading frame and to CDK4. Thus, barring any subtle deregulation of p16,
the phenotype of mice lacking exon 1b appears to behence p16 and p19ARF have no amino acid sequence
similarity. The open reading frame of the p19ARF tran- attributable directly to loss of the p19ARF transcript. Con-
versely, mice lacking exon 2 would be predicted to havescript is terminated within exon 2, with exon 3 compris-
ing an untranslated 39 exon (see Figure 2). p19ARF is lost both p16 and p19ARF, although in vitro studies have
suggested that, unlike exon 1b, exon 2 may not be criti-predicted to encode a basic polypeptide that has no
sequence homology toother known proteins, and shows cal to the function of p19ARF (Quelle et al., 1997). Clearly,
specific targeting of the unique p16 exon 1a will bez50% identity overall between human and mouse (com-
pared with 65% amino acid identity for p16). The protein required to determine definitively the relative contribu-
tions of these two transcripts to the knockout phe-is nuclear, with localization to subnuclear dots or speck-
les. Expression of the p19ARF transcript is ubiquitous notype.
p16 Versus p19ARFin postnatal tissues, in contrast to the more restricted
expression pattern of p16, and it appears to be elevated How can the consequences of inactivating p19ARF in the
mouse, namely tumorigenesis and cellular immortaliza-in cells lacking p53. While p19ARF does not bind to CDKs
or inhibit the activity of cyclin-CDK complexes, overex- tion, be reconciled with the compelling evidence derived
from human cancers which points to p16, rather thanpression results in a cell cycle arrest, both in G1 and
G2 (Quelle et al., 1995). However, p19ARF does not appear p19ARF, as the critical target? There is certainly ample
precedent for striking differences between mouse andto be specifically targeted by mutations in human can-
cer. Mutations have not been reported in the unique human phenotypes, particularly with respect to cancer
predisposition. However, given the functional conse-exon 1b, either in the germline of melanoma patients or
in sporadic tumors. While mutations in the shared exon 2 quences of disrupting p19ARF in the mouse, it would not
be unreasonable to expect that its loss may contributemay disrupt both p16 and p19ARF, no definitive mutations
have been found in p19ARF that do not also disrupt p16. to the transformed phenotype in the many tumors with
genomic deletions that span the p16-p19ARF locus (anChain-terminating mutations in p16 that encode a mis-
sense mutation in the p19ARF reading frame do not ap- argument that might be extended to p15 as well). While
p16 may be the essential target for malignant transfor-pear to alter the function of p19ARF, and in fact, exon 1b
alone appears sufficient to mediate cell cycle arrest by mation in a subset of human cancers, the loss of these
adjacent genes may lead to additional phenotypes thatp19ARF (Quelle et al., 1997). Promoter hypermethylation
has not been reported for p19ARF, which appears to be may be better understood once their specific functional
pathways have been defined.regulated by a promoter distinct from that directing ex-
pression of p16. The pendulum now swings back to defining the spe-
cific role of p16 in the mouse. It is possible that disrup-It is with this background that Kamijo and coworkers
specifically targeted exon 1b by homologous recombi- tion of exon 1a will have no phenotype, which would
attribute cellular immortalization and tumor develop-nation and observed a p19ARF-null phenotype that ap-
pears to recapitulate much of that observed following ment uniquely to the loss of p19ARF, and leave us scram-
bling to explain yet another difference between mousedisruption of exon 2, which is common to both p16
and p19ARF (Serrano et al., 1996). Thirty percent of mice and man. Alternatively, specific disruption of p16 may
lead to a phenotype similar to that reported followingdeveloped spontaneous lymphomas and sarcomas by
24 weeks, and 80% of DMBA-treated mice developed targeting of exon 2, since that exon is critical for p16
function and potentially dispensable for the mediationtumors between 9 and 20 weeks. Embryonic fibroblasts
derived from p19ARF-null mice failed to undergo crisis of cell cycle arrest by p19ARF (Quelle et al., 1997). The
possibility that both p16 and p19ARF might play indepen-after multiple passages in vitro and were efficiently
transformed by Ha-ras. Furthermore, MEFs derived from dent roles in the regulation of cell cycle progression and
cellular senescence is particularly intriguing. Cell cyclep19ARF heterozygotes lost the remaining wild-type allele
as they passed through crisis, supporting the impor- arrest by p19ARF appears to be abolished in cells lacking
p53, suggesting that it somehow acts upstream of p53tance of homozygous loss of p19ARF in cellular immortal-
ization. Taken together, these observations indicate that (Kamijo et al., 1997). The exact mechanism by which
p19ARF interacts with p53 is uncertain. Unlike the exclu-the phenotype resulting from disruption of both p16 and
p19ARF is comparable to that produced by disruption of sive inactivation of p16 and RB, the observation that
some tumors arising in p19ARF-null mice have mutationsp19ARF alone.
The targeting of adjacent genes, let alone different in p53 indicates that inactivation of these two genes is
not functionally equivalent. Nonetheless, like RB the p53transcripts from the same gene, can be a tricky busi-
ness. This is well illustrated by the variable phenotypes pathway has been implicated in cell cycle progression
and senescence. And here lies the most startling impli-of mice with different deletions of the myogenic factor
MRF4 gene, which are attributed to altered expression cation to emerge from the work of Kamijo and col-
of the neighboring gene Myf5 (see Olson et al., 1996). leagues, the possibility that a single gene ªp16-p19ARFº
However, Kamijo and coworkers demonstrate that ex- may reside at a crossroad of regulation for both RB
pression of the p16 transcript is not lost following disrup- and p53, through the use, unprecedented in mammalian
tion of exon 1b (if anything, the normal induction of cells, of overlapping distinct reading frames.
p16 expression following multiple passages in culture
is enhanced, an observation attributed to the loss of Selected Readings
competition for processing with the p19ARF transcript).
The p16 transcript in p19ARF-null mice is wild-type, and Duro, D., Bernard, O., Della Valle, V., Berger, R., and Larsen, C.-J.
(1995). Oncogene 11, 21±29.the encoded protein demonstrates theexpected binding
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